鹅膏蕈中毒治疗中苄青霉素血清浓度:抑制OATP1B3的药代动力学证据
该研究回顾性分析了2020-2024年佛罗伦萨毒物控制中心16例确诊鹅膏蕈中毒患者,均接受标准化多模式方案中的持续静脉苄青霉素输注(500,000 IU/kg/day×48h,随后250,000 IU/kg/day×48h)。44份血清样本用LC-MS/MS检测,前48小时所有样本浓度均超过OATP1B3抑制浓度IC50=25 µM,24h和48h平均浓度分别为265±87 µM和241±74 µM。减量后66%样本仍高于IC50,未观察到归因于苄青霉素的不良事件,所有患者存活出院且未行肝移植。结果提示持续输注在鹅膏毒蕈肝细胞摄取关键窗口期维持了药理学相关暴露。
要点
- 确诊鹅膏蕈中毒患者接受持续静脉苄青霉素500,000 IU/kg/day×48h后,24h平均血清浓度265±87 µM、48h为241±74 µM,均远超OATP1B3 IC50=25 µM。
- 前48小时所有血清样本均超过25 µM阈值,全部样本中位浓度176 µM(范围45-430 µM),93%样本超过25 µM。
- 剂量降至250,000 IU/kg/day后,平均浓度下降但66%样本仍高于IC50,提示减量方案在多数样本中维持抑制浓度。
- 16例患者均未观察到归因于苄青霉素的不良事件,全部存活出院且未接受肝移植。
- 该研究为回顾性、单中心、样本量16例的药代动力学分析,无对照组,不能据此确立临床疗效。
适用人群与场景
- 确诊鹅膏蕈中毒并在佛罗伦萨毒物控制中心接受标准化多模式治疗的患者(16例,2020-2024年)。
- 原文未提及排除人群、年龄范围、性别分布及中毒至治疗时间。
诊断标准与关键阈值
- 以体外报道的OATP1B3抑制浓度IC50=25 µM作为药代动力学目标阈值,比较血清苄青霉素浓度是否超过该值。
- 血清样本采用LC-MS/MS分析,浓度以µM表示。
处置流程与药物剂量
- 第一步:确诊鹅膏蕈中毒后启动标准化多模式方案,其中苄青霉素为持续静脉输注500,000 IU/kg/day,持续48小时。
- 第二步:随后48小时将苄青霉素持续静脉输注剂量降至250,000 IU/kg/day。
- 第三步:常规护理期间采集血清样本(n=44)用LC-MS/MS监测苄青霉素浓度,以25 µM为OATP1B3抑制阈值参考。
- 原文未提及多模式方案中其他药物的名称、剂量或具体给药方案。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的具体红旗征及对应处理。
研究设计与关键结果
- 研究类型:回顾性药代动力学分析;样本量16例患者、44份血清样本;单中心(佛罗伦萨毒物控制中心);无对照组。
- 干预:持续静脉苄青霉素500,000 IU/kg/day×48h后250,000 IU/kg/day×48h,作为标准化多模式方案的一部分。
- 主要药代结果:前48小时所有样本超过IC50=25 µM;24h平均浓度265±87 µM,48h平均浓度241±74 µM;全部样本中位浓度176 µM(范围45-430 µM),93%超过25 µM。
- 减量后结果:平均浓度下降,但66%样本仍高于25 µM。
- 安全性:未观察到归因于苄青霉素的不良事件;所有患者存活出院,未行肝移植。
证据类型、等级与局限
- 证据类型:回顾性、单中心、无对照的药代动力学分析(病例系列),样本量16例。
- 局限:回顾性设计、单中心、样本量小、无对照组、未报告中毒至治疗时间及临床疗效终点比较;原文未提及排除人群和混杂因素控制。
对床旁实践的改变
- 对确诊鹅膏蕈中毒并采用含苄青霉素多模式方案的患者,持续静脉输注500,000 IU/kg/day×48h可使血清浓度在前48小时均超过OATP1B3 IC50=25 µM,支持目标engaged。
- 减量至250,000 IU/kg/day后仅66%样本仍高于IC50,提示减量后部分患者可能低于抑制阈值,需结合原文未提及的个体化监测判断。
- 该研究不能证明苄青霉素的临床疗效(如降低肝移植或死亡),原文指出回顾性系列中临床疗效结果不一致,剂量方案和时机差异可能是原因之一。
- 适用人群为确诊鹅膏蕈中毒并接受标准化多模式治疗者;原文未提及不适用人群,不能外推至其他毒蕈中毒或未确诊患者。
指南或共识出处
- 原文未提及指南或共识名称;研究发表于Clin Toxicol (Phila)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Benzylpenicillin has long been included in treatment protocols for amatoxin poisoning based on experimental evidence suggesting inhibition of hepatocellular amatoxin uptake via OATP1B3. However, no human pharmacokinetic data have confirmed whether therapeutic regimens achieve serum concentrations sufficient to inhibit this transporter in vivo.
METHODS: We retrospectively analyzed serum benzylpenicillin concentrations in 16 patients with confirmed amatoxin poisoning treated at the Florence Poison Control Center between 2020 and 2024. All patients received continuous intravenous benzylpenicillin infusion (500,000 IU/kg/day for 48 h, followed by 250,000 IU/kg/day for 48 h) as part of a standardized multimodal protocol. Serum samples (n = 44) were collected during routine care and analyzed using LC-MS/MS. Concentrations were expressed in micromolar (µM) and compared with the reported OATP1B3 inhibitory concentration (IC50 = 25 µM).
RESULTS: During the first 48h, all serum samples exceeded the IC50 threshold, with mean concentrations of 265 ± 87 µM at 24 h and 241 ± 74 µM at 48 h. Across all samples, the median concentration was 176 µM (range 45-430 µM), and 93% exceeded 25 µM. Following dose reduction, mean concentrations declined but remained above the IC50 in 66% of samples. No adverse events attributable to benzylpenicillin were observed, and all patients survived to discharge without liver transplantation.
DISCUSSION: Although benzylpenicillin's clinical efficacy has yielded conflicting results across retrospective series, variability in dosing regimens and timing likely accounts for much of this inconsistency. The present findings demonstrate that continuous infusion maintains pharmacologically relevant exposure throughout the critical window of amatoxin hepatocellular uptake, supporting target engagement in vivo. The reduced-dose regimen sustained inhibitory concentrations in most samples, suggesting dose optimization is feasible without compromising pharmacological activity.
CONCLUSION: Continuous intravenous infusion of benzylpenicillin achieves serum concentrations exceeding the in vitro OATP1B3 inhibitory threshold in patients with amatoxin poisoning, providing human pharmacokinetic support for its proposed antidotal mechanism and its continued inclusion in multimodal treatment protocols.
参考来源
- Missanelli A, Crescioli G, Lanzi C, et al. Serum benzylpenicillin levels during treatment for amatoxin poisoning: pharmacokinetic support for OATP1B3 inhibition. Clin Toxicol (Phila). 2026. PMID: 42396640. doi:10.1080/15563650.2026.2688233
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。